I reiterate a 'Strong Buy' rating for Alcon with a one-year price target of $115 per share, driven by new product pipelines and FDA clearances. Alcon's Unity VCS/CS systems received FDA clearance, set ...
Alcon has experienced robust Q1 growth, driven by double-digit growth in vision care, particularly in the contact lens market. The company's strong revenue growth is attributed to successful product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback